World's Best Scientists 2026 revealed!
Thomas W. Dubensky

Thomas W. Dubensky

D-Index & Metrics

Microbiology

D-Index
60
Citations
14419
World Ranking
3103
National Ranking
1226

Thomas W. Dubensky publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Thomas W. Dubensky sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 151 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Thomas W. Dubensky D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas W. Dubensky sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 60 D-Index — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Thomas W. Dubensky is affiliated with Tempest Therapeutics in the United States. Their research spans multiple areas within biochemistry, genetics, molecular biology, and medicine, with a focus on pharmacology, cancer research, genetics, immunology, and oncology.

The scientist has contributed extensively to topics such as inflammatory mediators and NSAID effects, estrogen and related hormone effects, interferon and immune responses, cytokine signaling pathways and interactions, eicosanoids and hypertension pharmacology, as well as cancer metabolism related to hypoxia and lipids.

Recent publications highlight active involvement in clinical trials and cancer immunotherapy, including:

  • Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas (2021, Clinical Cancer Research)
  • Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors (2023, Cancer Research Communications)
  • First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors (2024, Cancer Research Communications)
  • A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. (2023, Journal of Clinical Oncology)
  • A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors. (2022, Journal of Clinical Oncology)

Frequent coauthorship collaborations include researchers such as Sam H. Whiting, Peppi Prasit, Brian J. Francica, Anja Holtz, and Nathan Standifer. These collaborations indicate a sustained engagement with a network of scientists working on similar or complementary research topics.

Thomas W. Dubensky has published repeatedly in prominent venues, with notable frequent publication outlets including:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research Communications

The profile of research undertaken reveals a multidisciplinary approach with an emphasis on the molecular and immunological mechanisms involved in cancer therapy and pharmacology, aligning with ongoing advancements in targeted clinical interventions and immunotherapies.

Best Publications

  • Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

    Leticia Corrales;Laura Hix Glickman;Sarah M. McWhirter;David B. Kanne

  • STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

    Juan Fu;David B. Kanne;Meredith Leong;Laura Hix Glickman

  • Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

    Dung T. Le;Andrea Wang-Gillam;Vincent Picozzi;Tim F. Greten

  • Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.

    Camie W. Chan;Emily Crafton;Hong Ni Fan;James Flook

  • The host STING pathway at the interface of cancer and immunity

    Leticia Corrales;Sarah M. McWhirter;Thomas W. Dubensky;Thomas F. Gajewski

  • Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

    Kelsey E. Sivick;Anthony L. Desbien;Laura Hix Glickman;Gabrielle L. Reiner

  • Listeria-based cancer vaccines that segregate immunogenicity from toxicity

    Dirk G. Brockstedt;Martin A. Giedlin;Meredith L. Leong;Keith S. Bahjat

  • Eukaryotic layered vector initiation systems

    Thomas W. Dubensky;John M. Polo;Carlos E. Ibanez;Stephen M. W. Chang

  • Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

    Wolfgang W. Leitner;Leroy N. Hwang;Michael J. deVeer;Aimin Zhou

  • A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

    Dung T. Le;Dirk G. Brockstedt;Ran Nir-Paz;Johannes Hampl

  • Adjuvants for cancer vaccines.

    Thomas W. Dubensky;Steven G. Reed

  • An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

    Silvia Perri;Catherine E. Greer;Kent Thudium;Barbara Doe

  • DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector

    Mangala J. Hariharan;David A. Driver;Kay Townsend;Duane Brumm

  • VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.

    Nicholas J. DePolo;Joyce D. Reed;Philip L. Sheridan;Kay Townsend

  • Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer.

    T. W. Dubensky;D. A. Driver;J. M. Polo;B. A. Belli

  • Recombinant alphavirus vectors

    Thomas W. Jr. Del Mar Dubensky;Carlos E. San Diego Ibanez;Stephen M.W. San Diego Chang;Douglas J. Leucadia Jolly

  • Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

    Jason R. Baird;David Friedman;Benjamin Cottam;Thomas W. Dubensky

  • Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

    Wolfgang W. Leitner;Han Ying;David A. Driver;Thomas W. Dubensky

  • Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells

    Monica V. Goldberg;Charles H. Maris;Edward L. Hipkiss;Andrew S. Flies

  • Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect

    Guoshun Wang;Vladimir Slepushkin;Joseph Zabner;Shaf Keshavjee

Frequent Co-Authors

Elizabeth M. Jaffee
Elizabeth M. Jaffee Johns Hopkins University
Daniel A. Portnoy
Daniel A. Portnoy University of California, Berkeley
Russell E. Vance
Russell E. Vance University of California, Berkeley
Michael A. Morse
Michael A. Morse Duke University
Herbert J. Zeh
Herbert J. Zeh The University of Texas Southwestern Medical Center
Charles G. Drake
Charles G. Drake Columbia University
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Drew M. Pardoll
Drew M. Pardoll Johns Hopkins University School of Medicine
Nina Bhardwaj
Nina Bhardwaj Icahn School of Medicine at Mount Sinai
Michael J. Gough
Michael J. Gough Providence Portland Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open diverse career pathways for those interested in the health sciences. For students wanting to combine microbiology knowledge with healthcare data management, pursuing a cahiim accredited him degree online is a strategic choice that ensures quality education aligned with industry standards.

For quicker entry into health administration roles, earning an online medical billing and coding certificate fast can be ideal. This certification opens doors to essential billing roles that support the healthcare system.

Additionally, students interested in clinical or specialized health professions can investigate what medical degrees can i get online. This resource offers insight into reputable programs available virtually, accommodating various career goals.

Finally, if public health appeals to you, considering the fastest and easiest online mph programs may provide a pathway to advance in epidemiology or health policy, complementing your microbiology background.

Best Scientists Citing Thomas W. Dubensky

Trending Scientists

Recently Published Articles